PhD Scientific Days 2026

Poster Session 2.M - Neurosciences

Oral Phenylephrine and Pregabalin Combination Alleviates Tactile Allodynia in Rats with Mononeuropathic Pain: A Promising Repurposing Strategy

Előadó neve

Ms. Abbood, Sarah

Neptune code

ANGGZ7

Előadó munkahelye

Semmelweis university

Előadó telefonszáma

06204008873

Előadó e-mail címe

abbood.sarah@phd.semmelweis.hu

Az előadás címe

Oral Phenylephrine and Pregabalin Combination Alleviates Tactile Allodynia in Rats with Mononeuropathic Pain: A Promising Repurposing Strategy

Szerző(k) neve és munkahelye

Sarah Kadhim Abbood¹, Judit Mária Kirchlechner-Farkasa¹, Imre Boldizsár¹, Kornél Király¹, Laszlo G Harsing Jr¹, E. Sylvester Vizi², Mahmoud Al-Khrasani¹

1: 1Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary, 2 Center for Pharmacology and Drug Research & Development, Semmelweis University, Budapest, Hungary
2: 1Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary, 3 Hun-Ren Institute of Experimental Medicine, Molecular Pharmacology Res. Group, Budapest, Hungary

Bemutatás módja

Poszter

Szekció

Poster Session 2.M - Neurosciences

Language of the presentation

English

Preferred session

Neurosciences

Összefoglaló szövege

Introduction: The high number needed to treat (NNT) the current pharmacotherapies for neuropathic pain (NP) necessitates developing novel combination-based approaches. Our previous work has highlighted the ability of phenylephrine (PE), a canonical α1-adrenoceptor agonist, to facilitate cytosolic noradrenaline (NA) release from spinal tissue, thus positioning it as a modulator of the endogenous spinal adrenergic system relevant to nociception. Pregabalin (PGB), a first-line treatment for NP that modulates voltage-gated calcium channels (VGCCs) containing the α2δ subunit, has a slow onset of action and limited efficacy at tolerable doses, as reflected by its high NNT. Investigating PE/PGB combinations to achieve effective pain relief is therefore of clinical value.
Aims: To evaluate the antiallodynic potential of orally administered PE, alone and in combination with PGB, in a rat model of mononeuropathic pain, and to assess the cardiovascular safety profile of the combination.
Methods: Mononeuropathic pain was induced in male Wistar rats via partial sciatic nerve ligation (pSNL). Tactile allodynia was assessed using the dynamic plantar aesthesiometer. Oral PE (5 mg/kg) and PGB (25 mg/kg) were administered individually and in combination, both acutely and chronically (for 7 days). The impact of the combination on the cardiovascular parameters, systolic and diastolic blood pressure, mean arterial pressure, and heart rate, was investigated in rats under isoflurane anaesthesia.
Results: Individual oral administration of PE (5 mg/kg) or PGB (25 mg/kg) failed to produce significant antiallodynic effects at the tested doses. However, their oral combination produced a significant antiallodynic effect with a rapid onset in pSNL rats, an effect further enhanced upon chronic administration. Finally, the PE/PGB combination did not alter the monitored cardiovascular parameters, namely systolic and diastolic blood pressure, mean arterial pressure, and heart rate.
Conclusions: Concurrent systemic administration of NA releasers like PE alongside VGCCs modulators such as PGB represents a promising treatment strategy for the management of NP. The favorable cardiovascular safety profile of the combination further supports its translational potential, warranting detailed pharmacokinetic and mechanistic investigation.
Funding: TKP2021-EGA-25

University

Semmelweis University

Supervisor

Mahmoud Al-Khrasani

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

phd.section.field

in doctoral studies after complex exam (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

8085

Start

18:54

End

18:57